At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Feb 22, 2026 at 19:00 ET
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and CMO, sold shares worth over $220K in the past week, following a large block of stock awards totaling over 450,000 shares. The sales appear to be part of a planned divestiture after recent vesting, signaling routine post-award selling rather than a negative outlook.
- CEO Marianne De Backer sold 19,039 shares for $141,894; also received 285,000 shares via award (likely vesting).
- CFO Jason O'Byrne, CMO Mark Eisner, General Counsel Vanina de Verneuil, and CAO Brent Sabatini each sold between 1,829 and 4,445 shares, totaling $220K in sales over 2 days.
- All five executives received substantial stock awards on 2026-02-22 at $0 price, indicating vesting of prior grants.
- Sales occurred at $7.4528 per share, consistent with market price, suggesting pre-arranged 10b5-1 plans or routine post-vest diversification.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access